TEMPORARY REMOVAL: Strategic Considerations for Achieving Consistent Performance of Transferred Assays in the Research Community

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Seminars in Oncology

• Publication date

  2016-06-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2016.06.009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.

  2016cited by this paper
• Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.

  2016cited by this paper
• Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations

  2014cited by this paper
• Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

  2014cited by this paper
• Abstract A214: Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Improved performance of the Top1 immunoassay for analysis of tumor biopsies.

  2013cited by this paper
• Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

  2012cited by this paper
• ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.

  2012cited by this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cited by this paper
• Development and validation of biomarker assays to assess pharmacodynamic modulation of MET.

  2011cited by this paper
• Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.

  2011cited by this paper
• AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

  2010cited by this paper
• Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

  2010cited by this paper
• Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Preclinical elopment of a Validated Immunofluorescence Assay γ H 2 AX as a Pharmacodynamic Marker of R oisomerase I Inhibitor Activity

  2010cited by this paper
• Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

  2010cited by this paper
• Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

  2009cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Next generation oncology drug development: opportunities and challenges

  2009cited by this paper
• Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.

  2009cited by this paper
• Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

  2008cited by this paper
• Validation of Analytic Methods for Biomarkers Used in Drug Development

  2008cited by this paper
• Compressing drug development timelines in oncology using phase '0' trials

  2007cited by this paper
• Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

  2007cited by this paper
• Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

  2006cited by this paper
• Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

  2004cited by this paper
• Send Orders of Reprints at Reprints@benthamscience.org Tissue-based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials

  year unknowncited by this paper

• No citing papers are available for this paper.